Press Releases

Date	Title
January 4, 2022	UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022 12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the second half of 2022 Phase 2 study of UBX1325 in wet AMD to include comparison with aflibercept